Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20.
The human breast cancer cells BT-20 were treated for 18 months in the continuous presence of interferon-gamma (HuIFN-gamma; 500 U/ml). These cells have become completely resistant to HuIFN-gamma and interestingly also to IFN-alpha 2. However, the expression of HLA-DR and the regulation of cell adhesion to tissue culture plastic remained partially under the domain of HuIFN-gamma. A reduced number of IFN-gamma binding sites in comparison to the wild-type cells were observed on the IFN-resistant BT-20 cells.
D001943:Breast Neoplasms; D002448:Cell Adhesion; D002460:Cell Line; D004351:Drug Resistance; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology*
D006684:HLA-DR Antigens; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma